Liisa Bayko
Stock Analyst at Evercore ISI Group
(4.37)
# 246
Out of 4,814 analysts
83
Total ratings
50%
Success rate
19.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $37.76 | +162.18% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $14.92 | +201.61% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.39 | +62.38% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.29 | +289.11% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.20 | +250.00% | 2 | Dec 11, 2024 | |
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $3.01 | +66.39% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $20.21 | +73.18% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $301.73 | +19.31% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $234.75 | +10.76% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $2.77 | -27.80% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.25 | +60.00% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $6.07 | +444.11% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $37.65 | +0.94% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $438 | $489.10 | -10.45% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $35.64 | +124.47% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $4.03 | +346.65% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $4.54 | +450.66% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $5.13 | +1,108.58% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.37 | +551.77% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $21.19 | +13.26% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $8.62 | +248.03% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.15 | +217.97% | 1 | Feb 5, 2020 |
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $37.76
Upside: +162.18%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $14.92
Upside: +201.61%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.39
Upside: +62.38%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.29
Upside: +289.11%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.20
Upside: +250.00%
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $3.01
Upside: +66.39%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $20.21
Upside: +73.18%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $301.73
Upside: +19.31%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $234.75
Upside: +10.76%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $2.77
Upside: -27.80%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.25
Upside: +60.00%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $6.07
Upside: +444.11%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $37.65
Upside: +0.94%
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $489.10
Upside: -10.45%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $35.64
Upside: +124.47%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $4.03
Upside: +346.65%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $4.54
Upside: +450.66%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $5.13
Upside: +1,108.58%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.37
Upside: +551.77%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $21.19
Upside: +13.26%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $8.62
Upside: +248.03%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.15
Upside: +217.97%